InVivoSIM anti-human Tissue Factor (CD142) (Tisotumab Biosimilar)

About InVivoSIM anti-human Tissue Factor (CD142) (Tisotumab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Tisotumab, making it ideal for research use. Tisotumab is a humanized IgG1 monoclonal antibody that reacts with human and monkey tissue factor (TF), also known as CD142, coagulation factor III (F3), and thromboplastin. TF is a single-pass transmembrane glycoprotein that is essential for initiating blood coagulation by forming a complex with circulating factor VII (F7) or serum prothrombin conversion accelerator (SPCA). This interaction converts the factor VII to VIIa, which follows the TF:VIIa complex-mediated activation of factors IX or X through proteolysis. Recent research has explored the involvement of CD142 in additional cellular signaling pathways responsible for tumor growth, e.g., mitogen-activated protein kinase (MAPK), phosphatidylinositol-3-kinase AKT (PI3K-AKT), and Wnt signaling pathways. TF shows aberrant expression in some tumors, and owing to its internalizing capacity, an in vivo study with patient-derived xenograft models of solid tumors has explored the potential of a monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADC) targeting TF for its anti-cancer activity. The tisotumab biosimilar is an antibody portion of an ADC called tisotumab vedotin, which is known for targeting the TF antigen, thereby directly delivering the cytotoxic microtubule-disrupting agent MMAE to cancer cells.